Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

779 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N. Imai Y, et al. Among authors: inada m. J Viral Hepat. 2010 Mar;17(3):185-91. doi: 10.1111/j.1365-2893.2009.01163.x. Epub 2009 Aug 26. J Viral Hepat. 2010. PMID: 19709362
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Inoue Y, et al. Among authors: inada m. J Viral Hepat. 2010 May;17(5):336-44. doi: 10.1111/j.1365-2893.2009.01182.x. Epub 2009 Aug 12. J Viral Hepat. 2010. PMID: 19678893
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T. Oze T, et al. Among authors: inada m. J Viral Hepat. 2015 Mar;22(3):254-62. doi: 10.1111/jvh.12289. Epub 2014 Jul 31. J Viral Hepat. 2015. PMID: 25081140
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.
Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y. Imai Y, et al. Among authors: inada m. Ann Intern Med. 1998 Jul 15;129(2):94-9. doi: 10.7326/0003-4819-129-2-199807150-00005. Ann Intern Med. 1998. PMID: 9669992
Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y. Yabuuchi I, et al. Among authors: inada m. Liver. 2000 Jul;20(4):290-5. doi: 10.1034/j.1600-0676.2000.020004290.x. Liver. 2000. PMID: 10959807
Changes in serum hepatic fibrosis markers in biochemical responders to interferon therapy for chronic hepatitis C.
Fukuzaki T, Kawata S, Imai Y, Tamura S, Inada M, Maeda H, Shirai Y, Maeda Y, Yabuuchi I I, Kiriyama K, Himeno S, Toyoshima H, Nishikawa M, Kashihara T, Minami Y, Nishiuchi M, Seki K, Matsuzawa Y. Fukuzaki T, et al. Among authors: inada m. Hepatol Res. 2000 May;17(2):156-166. doi: 10.1016/s1386-6346(99)00073-x. Hepatol Res. 2000. PMID: 10707009
779 results